List of Acuvail drug patents

Acuvail is owned by Allergan.

Acuvail contains Ketorolac Tromethamine.

Acuvail has a total of 4 drug patents out of which 0 drug patents have expired.

Acuvail was authorised for market use on 22 July, 2009.

Acuvail is available in solution/drops;ophthalmic dosage forms.

The generics of Acuvail are possible to be released after 15 August, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(1 year, 5 months from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(5 years from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's patent expiration?
More Information on Dosage

ACUVAIL family patents

30

United States

6

European Union

5

Australia

5

Spain

4

Poland

4

Japan

4

Canada

3

China

3

Denmark

2

Austria

2

Korea, Republic of

2

Brazil

2

New Zealand

1

Hong Kong

1

Malaysia

1

Ukraine

1

Germany

1

Israel

1

Mexico

1

Slovenia

1

Hungary

1

South Africa

1

Colombia

1

Russia

1

Croatia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic